Bayer hits Mylan with Nexavar lawsuit
Germany-based healthcare company Bayer HealthCare has sued Mylan Pharmaceuticals over the alleged infringement of five of its patents.
In a complaint filed on Thursday, December 17, at the US District Court for the District of Delaware, Bayer claimed that Mylan’s attempt to market a generic version of Nexavar (sorafenib) infringes its intellectual property.
Nexavar is used to treat kidney cancer and hepatocellular carcinoma, a type of cancer that affects the liver.
Mylan informed Bayer of its Abbreviated New Drug Application (ANDA) to market the Nexavar generic on November 5, 2015.
Bayer said: “Mylan’s notice letters did not provide a valid basis for concluding that the manufactu re, use offer for sale, sale, marketing distribution, and/or importation of Mylan’s ANDA product would not infringe at least one valid and enforceable claim” of the asserted patents.
The German company is seeking a declaration that the patents are valid and that the court award an injunction preventing Mylan from releasing its proposed generic.
